A Web-based and Mobile Environmental Management System

This paper describes a Web-based and mobile system specifically developed to monitor fish species at risk. Such a system integrates spatial functionality to allow users not only to visualise maps and metadata of the area of concern but also to perform context-aware queries and updating of spatial datasets. The spatial datasets are provided by the Canadian Department of Fisheries and Oceans (DFO) and the prototype is customised to the specific needs of the Great Lakes Laboratory for Fisheries and Aquatic Sciences (GLLFAS) Fish Habitat Section requirements for fish species at risk assessment. Currently, researchers, habitat biologists and enforcement officers have access to the fisheries database, containing layers of biological information solely from the office. Delivering these data overlaid on base maps of the Great Lakes region to a GPS-enabled hand-held device and linking it to each task currently being investigated allows for mobile DFO biologists and enforcement officers in the field to make informed decisions immediately. In this paper we describe the system and demonstrate how it is used by the DFO in practice

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients

Abstract Autologous hematopoietic stem cell transplantation (AHSCT) has been used in the treatment of highly active multiple sclerosis (MS) for over two decades. It has been demonstrated to be highly efficacious in relapsing–remitting (RR) MS patients failing to respond to disease-modifying drugs (DMDs). AHSCT guarantees higher rates of no evidence of disease activity (NEDA) than those achieved with any other DMDs, but it is also associated with greater short-term risks which have limited its use. In the 2019 updated EBMT and ASBMT guidelines, which review the clinical evidence of AHSCT in MS, AHSCT indication for highly active RRMS has changed from “clinical option” to “standard of care”. On this basis, AHSCT must be proposed on equal footing with second-line DMDs to patients with highly active RRMS, instead of being considered as a last resort after failure of all available treatments. The decision-making process requires a close collaboration between transplant hematologists and neurologists and a full discussion of risk–benefit of AHSCT and alternative treatments. In this context, we propose a standardized protocol for decision-making and informed consent process

The added value of simultaneous palpation during scrotal ultrasound

N/

Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients

n/